Literature DB >> 25882221

Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges.

Prathesha Pillai, R S Surenya, Shantikumar V Nair, Vinoth-Kumar Lakshmanan1.   

Abstract

Cancer kinome is now well organized as an important target for a new class of cancer drugs. There are more than 500 members in the kinase family in which some of them are clinically analysed, while the rest are under investigation for potential therapeutic applications. Phosphorylation, major function of kinases is one of the most significant signal transduction mechanism in which intercellular signals regulate intracellular processes like ion transport, hormone responses and cellular proliferation. Any deregulation of kinase function may lead to tumor progression and other disorders such as immunological, neurological , metabolic including also infectious diseases. This led to the necessity in the development of kinase inhibitors as therapeutic agent. Herein we discuss about different types of kinases and their inhibitors in various types of cancers. This review portrays a broad overview of the origin of kinases, discovery, the characterization and mode of action of kinase inhibitors in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25882221     DOI: 10.2174/1389450116666150416120108

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  5 in total

Review 1.  Inter-proteomic posttranslational modifications of the SARS-CoV-2 and the host proteins ‒ A new frontier.

Authors:  Suresh Mishra; Geetika Bassi; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-19

2.  Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines.

Authors:  Francesca Benedetti; Sabrina Curreli; Robert C Gallo; Davide Zella
Journal:  J Transl Med       Date:  2021-02-09       Impact factor: 5.531

3.  MELK is a novel therapeutic target in high-risk neuroblastoma.

Authors:  Shan Guan; Jiaxiong Lu; Yanling Zhao; Yang Yu; Hui Li; Zhenghu Chen; Zhongcheng Shi; Haoqian Liang; Mopei Wang; Kevin Guo; Xiangmei Chen; Wenjing Sun; Shayahati Bieerkehazhi; Xin Xu; Surong Sun; Saurabh Agarwal; Jianhua Yang
Journal:  Oncotarget       Date:  2017-12-20

4.  Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.

Authors:  Immacolata Andolfo; Vito A Lasorsa; Francesco Manna; Barbara E Rosato; Daniela Formicola; Achille Iolascon; Mario Capasso
Journal:  J Cell Mol Med       Date:  2020-04-26       Impact factor: 5.310

5.  Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status.

Authors:  Katharina Alack; Astrid Weiss; Karsten Krüger; Mona Höret; Ralph Schermuly; Torsten Frech; Martin Eggert; Frank-Christoph Mooren
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.